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the total time that the immediate and deferred groups
spent on zidovudine. They contend that, if the efficacy
of zidovudine depended on the duration of its
administration, the _ relatiyely_ small - exposnre to
zidovudine before AIDS or ARG appeared in the deferred
group would have had little effect. Second, they argue
that, if zidovudine were efficacious and its efficacy
depended on a particular aspect of disease progression
such äs a low CD4 count, the CD4 count would have to
be below 300/μί, since 82% of the patients in the deferred
group started zidovudine at CD4 counts of 300 or less.
There was no relation between CD4 counts and long-
term efficacy of zidovudine.
Despite the change in protocol, analysis of the study
was based on Intention to treat. Although this is a valid
technique, this aspect of study methods in general has
been described äs "perhaps the chief source of
misunderstanding between statisticians and clinicians
about the logic of trial design".7 This method of analysis is
appropriate for the Concorde trial and at the very least
may have saved numerous arguments about which
subgroup should have been included or not. The clinical
trial design of Concorde has an ironic aspect in diät the
exclusion criteria included pregnancy. From the
announced outcome of an unpublished study, zidovudine
given to the mother during pregnancy reduces the
transmission of HIV to the fetus, so a group who might
have benefited most from the Concorde study was
excluded.
The results showed that, after a median follow-up of
3-3 years, survival was not statistically significantly
different between the two groups, with estimated 3-year
probabilities of death of 8% in the immediate group and
6% in the deferred group. Progression to AIDS or ARG
was likewise similar in the two groups. In a separate
analysis of data from the first year, there was a slight
advantage to being in the immediate group, with a relative
risk (immediate/deferred) of 0-77 at l year which lost
statistical significance by 18 months. Although there was
a consistent difference in CD4 counts, there was no
relation between this and a delay in progression of
disease.
When a study finds no difference between two groups,
one has to consider issues related to the type II or beta
error—ie, what is the chance that a difference between the
two groups was missed. Of course it is easier to obtain a
statistically significant result with larger differences than
with smaller ones. Concorde was designed to detect a
one-third relative reduction in the rate of progression of
disease. From the results, the researchers say that it would
have been unlikely for them to have missed a 22%
reduction in progression of disease in the immediate
group. Since no statistically significant increase in
mortality in the immediate group was observed, a relative
reduction of more than 9% was judged unlikely. .
There is a practical issue in how large a clinical trial can
be so äs to detect a very small difference between two
groups. However, with a disease äs devastating äs AIDS, a
chance of even a 5% reduction in progression may be
attractive to an HlV-infected individual. Nevertheless, in
taking a chance with treatment, the side-effects of that
therapy should be taken into account. Concorde indicates
an increased incidence of adverse events in those in tue
immediate group and the researchers question the impact
on the quality of life of those taking zidovudine.
Lenderking et ala examined retrospectively a study on
zidovudine treatment in symptom-free HIV infection by
survival analysis adjusted for the _ quality of life. They
concluded that there was a reduction in quality of life for
symptom-free individuals taking 500 mg of zidovudine a
day which equalled a short-term gain in disease
progression.
The findings of Concorde do not differ from other trials
of symptom-free individuals when examined at l year.
Concorde indicates that the benefit is not lasting, because
at 3 years there is little difference between the immediate
and the delayed groups. As pointed out previously' and
referred to in the present study, what is needed is a longer
follow-up period to determine what effect the two
interventions have subsequently on disease progression
and mortality.2 The question of viral resistance to
zidovudine may be related to disease progression.
Concorde did not examine viral resistance, but this aspect
could usefully be studied during extended follow-up.
Overall, Concorde does not provide compelling
evidence that zidovudine is of great use in non-pregnant
symptom-free adults with HIV infection.
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Anticoagulation: how low can one go?
See page 886
The high risk of venous thrombosis in patients with
advanced cancer presents a therapeutic challenge.
Clinicians wish to spare their patients any additional
suffering not only from thrombosis but also from intensive
treatment or monitoring and from bleeding. Thrombosis
prophylaxis with low-dose warfarin, äs described in this
issue by Levine and colleagues, may provide the answer.
Levine et al show that this method is effective and safe.
Moreover, oral administration is less troublesome than
' subcutaneous injections with heparin. Warfarin (and
other" coumarin derivatives) inhibits the production of all
vitamin-K-dependent clotting factors.' The effect of a
very low dose does not depend on homoeopathy: even at
an international normalised ratio (INR) of 1-5 clotting
factor concentrations are reduced to 50-70% of normal,2
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and this reduction now proves to be sufficient for
substantial protection against thrombosis. - '
The trend towards less intense anticoagulation has two
objectives: (a) to diminish the risk of bleeding, which is
closely related to the intensity;3 and (£>) with a fixed-dose,
to render frequent monitoring unnecessary. The fixed-
dose approach was tried by Poller et al4 for thrombosis
prophylaxis after gynaecological surgery: one'group of
patients received a fixed dose of warfarin l mg daily, and
this regimen was compared with controls without
anticoagulation " and " also with anticoagulation in
conventional target ranges (INR 2-4). Low-dose warfarin
proved effective compared with no treatment
(thromboses: 3/32 vs 11/37) but was less effective than
full-dose anticoagulation (thromboses: >3/32 vs 1/35).
Although the fixed low-dose strategy has clear advantages,
it cannot be the first choice because of the great individual
variability in doses required to obtain an effect on the
clotting System, äs confirmed by the broad dose ränge
reported by Levine et al. Poller's study suggests that very-
low-dose warfarin is effective, but not äs effective äs more
intense anticoagulation. The same conclusion can be
inferred from studies that showed no protective effect of a
fixed low-dose warfarin regimen.5
The key question now, for all indications, is which
intensity of anticoagulation offers the Optimum result in
terms of balance between effect and side-effect.6 This
answer'cannot come from a simple comparison of two
target INR levels in a randomised trial: in such a study
only two rather arbitrary target intensities are compared,
and, more important, the true pharmacological effect is
mixed with, or even masked by, imperfect compliance and
anticoagulant control. Such factors make Interpretation of
results difficult, especially when the two target intensities
perform equally well.7 These trials typically use intention-
to-treat analyses; the intensity of anticoagulation actually
achieved is not taken into account.
Schwartz and Lellouch8 classified trials äs explanatory
and pragmatic. In explanatory trials conditions are
optimised äs in the laboratory to determine the
pharmacological effect of a drug. In pragmatic trials
conditions are accepted äs they are—ie, resembling daily
practice—to determine the effect of routine prescribing.
These study types differ in design, conduct, size, and
analysis: a pragmatic trial will be subjected to an
intention-to-treat analysis whereas on-treatment analysis
will be used for an explanatory trial
In oral anticoagulant treatment there is a clear need for
explanatory studies. For many indications we now know
that coumarin derivatives are effective in preventing
thromboembolism—but effectiveness cannot be equated
with Optimum effect. The preferable on-treatment
analysis would require researchers to estimate the risk of
untoward events at different achieved intensities. Since
INRs vary considerably over time in individual patients, a
new method is needed in which "time-spent-at-each-
INR" becomes the unk of analysis. Such an approach has
recently been developed' and is being used in several
studies.10·" This approach may be pragmatic äs well äs
explanatory, since it can be applied within a randomised
trial (äs for on-treatment analysis) and also on routine
data from anticoagulant clinics.3·' _ „··
Once we know the optimum achieved intensity of
anticoagulation for various indications, subsequent
research should focus at how to achieve these intensities,
which remains a major challenge.
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Microfilaria, tolerance, and T cells
See page 890
As shown by Steel and colleagues in this issue, prenatal or
perinatal exposure to microfilarial antigens leads'to long-
term reduction in T-cell responses in vitro but with
preserved or enhanced serum antibody concentrations.
The effect is specific for antigens restricted to one stage of
parasite J.-\vlop::io:ii, i : i i . l 1:1 ·> f x j O n i n tru- nbsence of
certain ϊ:ι;1ίΐΐ!ΐιιι;Γ.ϊ<)!ΐ-ιΙν.·:ν!:>Κ·:ιι comj'üi.iiiion»· such äs
elephantiasis when such ip.lividii.ii« bccomo infected aiVr
birth. Various matema! ink'i.iio:!·» c.in ί ϊ ΐΓί ι ιοικν tlu
subsequeni inmuno'.odrnl rc^ponsiveness £ of· the
offspring.1 Sonu'üme·· ir.iii~pliK.vu·:)! infection of the fetus
is responsible but this do'es not seem to be the case with
microfilaria. Jndeed, the immune System of the human
fetus can be sensitised to protein antigens of tetanus
toxoid injected into the mother.1·2 In this example, T-cell
responses are enhanced, whereas in the report of Steel et
al such responses, äs assessed by proliferation and
cytokine production, are reduced. , , , '.
Notwithstanding the potentially important implications
for pathogenesis, the most interesting aspects of reduced
T-cell responses after exposure to microfilarial antigen are
speculations about underlying fundamental mechanisms
of tolerance induction. Steel et al suggest deletion or
paralysis of, antigen-specific precursors of functional
T-cell clones by exposure to microfilarial antigen in utero.
A similar mechanism may play an important part in
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